The cost of Praluent (alirocumab) without insurance can vary significantly depending on the dosage and the pharmacy. Without insurance, a one-month supply of Praluent typically ranges from approximately $600 to $800. For example, the 75 mg dose might cost around $627, while the 150 mg dose could be closer to $777 [1].
What factors influence Praluent's out-of-pocket cost?
The retail price of Praluent is influenced by several factors. These include the specific dosage prescribed, as higher doses generally cost more. The pharmacy where the prescription is filled also plays a role, as different pharmacies may have varying pricing structures. Additionally, any available manufacturer coupons or patient assistance programs could reduce the final cost for eligible individuals, although these typically require some form of prescription coverage or specific eligibility criteria.
Are there ways to get Praluent for less if uninsured?
While Praluent's out-of-pocket cost without insurance is substantial, some programs may offer assistance. The manufacturer, Sanofi, offers a Savings Card for eligible patients, which can help reduce co-pays. However, eligibility for these savings programs often depends on factors like insurance status and income. Individuals without insurance should inquire directly with Sanofi or explore discount card options that can sometimes be applied to prescription medications. Information on such programs can often be found on the drug's official website or through patient advocacy groups.
What is Praluent used for?
Praluent is a prescription medication used to lower low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol. It is indicated for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who are on maximally tolerated statin therapy or for whom statins are contraindicated [2]. It works by inhibiting PCSK9, a protein that reduces the number of LDL receptors in the liver, thereby increasing the liver's ability to remove LDL cholesterol from the blood [3].
How does Praluent's price compare to other cholesterol-lowering drugs?
Praluent is a PCSK9 inhibitor, a class of drugs that are generally more expensive than traditional cholesterol-lowering medications like statins. For instance, statins are available in generic forms and are significantly less costly. When compared to other PCSK9 inhibitors, such as Repatha (evolocumab), pricing can be similar, though specific costs may fluctuate. The higher cost of Praluent and similar drugs reflects their novel mechanism of action and the extensive research and development required for their approval [1].
When does Praluent's patent protection end?
Information regarding the specific patent expiry dates for Praluent is complex and can involve multiple patents covering different aspects of the drug, such as its composition, method of use, and manufacturing. DrugPatentWatch.com provides detailed patent information and expiration timelines for pharmaceuticals. For precise Praluent patent expiry dates, consulting resources like DrugPatentWatch.com is recommended, as it tracks these critical dates which are essential for understanding when generic competition might emerge [1].
Sources:
[1] DrugPatentWatch.com
[2] Sanofi US
[3] National Institutes of Health